Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it Life sciences companies are putting all of their efforts into finding a treatment or developing a vaccine for this disease PharmaShots is keeping a track of all of the important updates in the Life-sciences […]Read More
Shots: The US FDA has put a partial clinical hold on P-II/III study of Inovio’s INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial because it has additional questions about the trial Inovio is actively working to address the FDA’s questions and plans to respond in Oct’2020 after which the FDA […]Read More
The second quarter of 2020 has ended with big approvals in pharma and biotech industry. Moving with the latest approval of Roche’s Phesgo and Enspryng & Zogenix’s Fintepla. Highlights of the quarter is COVID-19 as the development of vaccines and drugs were on peak. Celltrion evaluated Remsima (biosimilar, infliximab) against COVID-19 in the UK. The […]Read More
The emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and kits This article covers the last six months of deal data provided by Chris Dokomajilar of DealForma During the last six months […]Read More
1. Novartis Reports Results of Enerzair Breezhaler (QVM149) in P-IIIb ARGON Study to Treat Uncontrolled Asthma Published: Jun 04, 2020 | Tags: Novartis, Reports, Enerzair Breezhaler, QVM149, P-IIIb, ARGON Study, Treat, Uncontrolled Asthma 2. Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals Published: Jun 04, 2020 | Tags: Melinta Therapeutics, Acquire, Tetraphase Pharmaceuticals 3. AstraZeneca Signs an Agreement with […]Read More
Shots: Inovio and IVI collaborate with Seoul National University Hospital to begin P-I/II clinical study of INO-4800 in South Korea The P-II study will assess the safety, tolerability, and immunogenicity of the INO-4800 vaccine in 40 adults aged 19-50 yrs. and will expand to enroll an additional 120 people aged 19-64 yrs. the companies expect […]Read More
ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa Published: Jan 30, 2020 | Tags: ProQR, QR-421a, Receives, FDA, Rare Pediatric Disease Designation, Retinitis Pigmentosa 2. Eli Lilly’s Fast-Acting Insulin Lispro Receives CHMP’s Positive Opinion in Patients with Diabetes Published: Jan 31, 2020 | Tags: Eli Lilly, Fast Acting Insulin Lispro, Receives, CHMP, Positive Opinion, […]Read More
Shots: Inovio is currently evaluating INO-4800 vaccine in P-I study assessing its safety and immunogenicity in the US and is supported by a grant of ~$9M from the Coalition for Epidemic Preparedness Innovations (CEPI) The focus of the collaboration is to deploy Advaccine’s expertise to initiate P-I study in China in parallel with its clinical […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
